AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BridgeBio to Showcase ATTRibute-CM Study Results at ESC Congress 2025
ByAinvest
Thursday, Aug 28, 2025 5:33 am ET1min read
BridgeBio Pharma will present additional data from its ATTRibute-CM study at ESC Congress 2025. The presentations will highlight Month 42 cardiovascular mortality results and Month 30 improvements in NT-proBNP. Key presenters include experts from Stanford University, UChicago Medicine, and University College London. The study focuses on assessing the efficacy of acoramidis in treating cardiomyopathy in wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).
BridgeBio Pharma, Inc. (Nasdaq: BBIO) has announced that it will present new data on its drug, Acoramidis, during the European Society of Cardiology (ESC) Congress 2025 in Madrid from August 29 to September 1. The presentations will highlight the drug's impact on reducing cardiovascular mortality and improving NT-proBNP levels in patients with transthyretin-mediated amyloidosis (ATTR-CM) [1].The presentations will include a rapid oral presentation on the drug's impact on reducing cardiovascular mortality from the ATTRibute-CM study at Month 42, as well as two ePosters detailing its effectiveness at Month 30 in improving NT-proBNP levels and beneficial effects on ATTR stage in patients with ATTR-CM [1]. The key presenters include experts from Stanford University, UChicago Medicine, and University College London [1].
Acoramidis is a transthyretin stabilizer aimed at reducing cardiovascular death and hospitalizations in adults with ATTR-CM. The company has shared that common adverse reactions include diarrhea and upper abdominal pain, primarily mild in nature [1].
The participation at the European Society of Cardiology Congress enhances visibility and credibility within the medical community, potentially attracting interest from healthcare professionals and investors. New data from the study may provide further validation of Acoramidis's efficacy, supporting its use and possibly leading to increased adoption among physicians treating ATTR-CM patients [1].
References:
[1] https://www.quiverquant.com/news/BridgeBio+Pharma+to+Present+New+Data+on+Acoramidis+at+ESC+Congress+2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet